AbbVie Inc. (ABBV) stock analysis

AbbVie Inc. — Healthcare · Drug Manufacturers—General carries a Plainview business-quality score of 6.0/10, built deterministically from SEC filings and Yahoo Finance: revenue, margins, cash, valuation, and a confluence buy zone. The live X-Ray loads below.

On the fundamentals, AbbVie Inc. shows trailing revenue of $62.82B, a 72.0% gross margin, net debt of $54.84B, EPS of 2.05, valued at about 7.4x times sales. X-Ray measures business quality only — momentum and entry timing live in Decide and Opportunity Cost.

• Current Price: $263.30
• YTD Return: +14.8%
• Revenue TTM: $62.82B
• Revenue Trend: YoY -2.7%
• Gross Margin: 72.0%
• Net Cash: $-54.84B
• EPS: 2.05
• P/S Ratio: 7.4x

Compare: ABBV vs UNH · ABBV vs JNJ · ABBV vs LLY | Also: UNH, JNJ, LLY, PFE, MRK, TMO